CN1251045A - 用于抗细胞增生剂的凝胶释药赋形剂 - Google Patents
用于抗细胞增生剂的凝胶释药赋形剂 Download PDFInfo
- Publication number
- CN1251045A CN1251045A CN98803660A CN98803660A CN1251045A CN 1251045 A CN1251045 A CN 1251045A CN 98803660 A CN98803660 A CN 98803660A CN 98803660 A CN98803660 A CN 98803660A CN 1251045 A CN1251045 A CN 1251045A
- Authority
- CN
- China
- Prior art keywords
- excipient
- compositions
- agent
- host
- thickening agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims (34)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/803,128 | 1997-02-20 | ||
US08/803,128 US6630168B1 (en) | 1997-02-20 | 1997-02-20 | Gel delivery vehicles for anticellular proliferative agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1251045A true CN1251045A (zh) | 2000-04-19 |
CN1212154C CN1212154C (zh) | 2005-07-27 |
Family
ID=25185657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB988036606A Expired - Fee Related CN1212154C (zh) | 1997-02-20 | 1998-02-19 | 用于抗细胞增生剂的凝胶释药赋形剂 |
Country Status (13)
Country | Link |
---|---|
US (4) | US6630168B1 (zh) |
EP (1) | EP0971745B1 (zh) |
JP (1) | JP2001512487A (zh) |
KR (1) | KR100611137B1 (zh) |
CN (1) | CN1212154C (zh) |
AT (1) | ATE308996T1 (zh) |
AU (1) | AU746938B2 (zh) |
CA (1) | CA2281919A1 (zh) |
DE (1) | DE69832266T2 (zh) |
HK (1) | HK1026142A1 (zh) |
NO (1) | NO994015L (zh) |
NZ (1) | NZ337875A (zh) |
WO (1) | WO1998036776A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107429154A (zh) * | 2015-09-18 | 2017-12-01 | 亨斯迈石油化学有限责任公司 | 改进的聚(乙烯基己内酰胺)动力学气体水合物抑制剂及其制备方法 |
CN111770752A (zh) * | 2018-10-16 | 2020-10-13 | 美国纳米食品药品公司 | 瘤内注射制剂 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6630168B1 (en) * | 1997-02-20 | 2003-10-07 | Biomedicines, Inc. | Gel delivery vehicles for anticellular proliferative agents |
US6040330A (en) * | 1999-01-08 | 2000-03-21 | Bionumerik Pharmaceuticals, Inc. | Pharmaceutical formulations of taxanes |
US20020192280A1 (en) * | 2001-05-01 | 2002-12-19 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents |
AU2002323266B2 (en) * | 2001-08-20 | 2008-04-24 | Transave, Inc. | Method for treating lung cancers |
US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
CN1607937A (zh) * | 2001-10-19 | 2005-04-20 | 爱德士实验室公司 | 用于药理活性化合物的可控释放的可注射组合物 |
US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
EP1545459A4 (en) * | 2002-08-02 | 2007-08-22 | Transave Inc | PLATINUM AGGREGATES, AND METHOD FOR MANUFACTURING THE SAME |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
EP1682012A4 (en) * | 2003-11-13 | 2008-09-24 | Alza Corp | COMPOSITION AND APPARATUS FOR TRANSDERMAL DELIVERY |
US20040224019A1 (en) * | 2004-03-03 | 2004-11-11 | Adi Shefer | Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs |
US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
US20050249822A1 (en) * | 2004-03-18 | 2005-11-10 | Transave, Inc. | Administration of cisplatin by inhalation |
CA2566174A1 (en) * | 2004-05-21 | 2005-12-01 | Transave, Inc. | Treatment of lung diseases and pre-lung disease conditions |
CA2570599C (en) * | 2004-06-24 | 2012-03-27 | Idexx Laboratories, Inc. | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
US7854943B2 (en) | 2004-06-24 | 2010-12-21 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
US7858115B2 (en) | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
US7618651B2 (en) | 2004-06-24 | 2009-11-17 | Idexx Laboratories | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same |
MX2007004955A (es) * | 2004-11-08 | 2007-06-14 | Transave Inc | Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente. |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
WO2007056263A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
WO2007056236A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
WO2007056264A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
US20070122350A1 (en) * | 2005-11-30 | 2007-05-31 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
WO2007124372A2 (en) * | 2006-04-20 | 2007-11-01 | Transport Pharmaceuticals, Inc. | Pharmaceutical formulations for iontophoretic methotrexate delivery |
WO2014039533A2 (en) | 2012-09-04 | 2014-03-13 | Eleison Pharmaceuticals, Llc | Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin |
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
US20160346221A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
IN202121042020A (zh) * | 2021-09-17 | 2023-03-24 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3888995A (en) * | 1968-07-19 | 1975-06-10 | Syntex Corp | Fatty alcohol-propylene glycol vehicle |
CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
US4619913A (en) | 1984-05-29 | 1986-10-28 | Matrix Pharmaceuticals, Inc. | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
JPS6219528A (ja) | 1985-07-16 | 1987-01-28 | Kurorera Kogyo Kk | 制癌剤 |
DE3603444A1 (de) * | 1986-02-05 | 1987-08-06 | Thomae Gmbh Dr K | Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha |
JPH0730029B2 (ja) * | 1986-09-08 | 1995-04-05 | 株式会社クラレ | 1−置換アザシクロヘプタン−2−オン及びこれを含有する経皮投与用薬剤 |
DE3631413A1 (de) | 1986-09-16 | 1988-03-24 | Knoll Ag | Therapeutisches system zur lokalen applikation von pharmawirkstoffen |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5051257A (en) | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
US5487897A (en) * | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
CA2061566C (en) | 1992-02-20 | 2002-07-09 | Rudolf E. Falk | Treatment of disease employing hyaluronic acid and nsaids |
GB9310049D0 (en) | 1993-05-12 | 1993-06-30 | Cancer Res Campaign Tech | Growth factor effects |
JPH09507233A (ja) * | 1993-12-29 | 1997-07-22 | マトリクス ファーマスーティカル,インコーポレイティド | 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物 |
DK0754032T3 (da) * | 1994-04-08 | 2002-04-02 | Atrix Lab Inc | Flydende frigivelsessammensætninger |
US5603955A (en) * | 1994-07-18 | 1997-02-18 | University Of Cincinnati | Enhanced loading of solutes into polymer gels |
US5567420A (en) * | 1994-11-16 | 1996-10-22 | Mceleney; John | Lotion which is temporarily colored upon application |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
AU7735298A (en) | 1996-12-17 | 1998-07-15 | Lidak Pharmaceuticals | Use of C18 to C26 aliphatic alcohols for the manufacture of medicament in the t reatment of hyperproliferative skin disorders |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
US6630168B1 (en) * | 1997-02-20 | 2003-10-07 | Biomedicines, Inc. | Gel delivery vehicles for anticellular proliferative agents |
-
1997
- 1997-02-20 US US08/803,128 patent/US6630168B1/en not_active Expired - Fee Related
-
1998
- 1998-02-19 WO PCT/US1998/003107 patent/WO1998036776A2/en not_active Application Discontinuation
- 1998-02-19 NZ NZ337875A patent/NZ337875A/en unknown
- 1998-02-19 AU AU66583/98A patent/AU746938B2/en not_active Ceased
- 1998-02-19 KR KR1019997007602A patent/KR100611137B1/ko not_active IP Right Cessation
- 1998-02-19 CN CNB988036606A patent/CN1212154C/zh not_active Expired - Fee Related
- 1998-02-19 JP JP53681598A patent/JP2001512487A/ja not_active Ceased
- 1998-02-19 AT AT98908583T patent/ATE308996T1/de not_active IP Right Cessation
- 1998-02-19 CA CA002281919A patent/CA2281919A1/en not_active Abandoned
- 1998-02-19 EP EP98908583A patent/EP0971745B1/en not_active Expired - Lifetime
- 1998-02-19 DE DE69832266T patent/DE69832266T2/de not_active Expired - Fee Related
-
1999
- 1999-08-19 NO NO994015A patent/NO994015L/no unknown
-
2000
- 2000-02-16 US US09/505,303 patent/US6669958B1/en not_active Expired - Fee Related
- 2000-08-30 HK HK00105425A patent/HK1026142A1/xx not_active IP Right Cessation
-
2003
- 2003-09-03 US US10/654,690 patent/US20040076679A1/en not_active Abandoned
- 2003-12-18 US US10/741,284 patent/US20040131646A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107429154A (zh) * | 2015-09-18 | 2017-12-01 | 亨斯迈石油化学有限责任公司 | 改进的聚(乙烯基己内酰胺)动力学气体水合物抑制剂及其制备方法 |
CN107429154B (zh) * | 2015-09-18 | 2020-11-20 | 亨斯迈石油化学有限责任公司 | 改进的聚(乙烯基己内酰胺)动力学气体水合物抑制剂及其制备方法 |
CN111770752A (zh) * | 2018-10-16 | 2020-10-13 | 美国纳米食品药品公司 | 瘤内注射制剂 |
Also Published As
Publication number | Publication date |
---|---|
KR100611137B1 (ko) | 2006-08-10 |
CN1212154C (zh) | 2005-07-27 |
NO994015L (no) | 1999-10-15 |
CA2281919A1 (en) | 1998-08-27 |
EP0971745B1 (en) | 2005-11-09 |
NZ337875A (en) | 2001-09-28 |
JP2001512487A (ja) | 2001-08-21 |
US6630168B1 (en) | 2003-10-07 |
DE69832266T2 (de) | 2006-08-03 |
WO1998036776A2 (en) | 1998-08-27 |
EP0971745A2 (en) | 2000-01-19 |
WO1998036776A3 (en) | 1998-11-26 |
NO994015D0 (no) | 1999-08-19 |
ATE308996T1 (de) | 2005-11-15 |
AU6658398A (en) | 1998-09-09 |
KR20000075543A (ko) | 2000-12-15 |
DE69832266D1 (de) | 2005-12-15 |
US6669958B1 (en) | 2003-12-30 |
AU746938B2 (en) | 2002-05-09 |
US20040076679A1 (en) | 2004-04-22 |
HK1026142A1 (en) | 2000-12-08 |
US20040131646A1 (en) | 2004-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1251045A (zh) | 用于抗细胞增生剂的凝胶释药赋形剂 | |
CN1161102C (zh) | 系统作用的局部用激素组合物 | |
CN1268336C (zh) | 用于口服给予埃坡霉素的药用组合物、剂型以及方法 | |
CN1196484C (zh) | 联合用作抗癌剂的药物组合物 | |
CN1173742C (zh) | 缓释药物组合物 | |
CN1245958C (zh) | 控释羟可酮组合物 | |
CN1189216C (zh) | 含血浆蛋白的药物组合物 | |
CN101031283A (zh) | 用于递药的药用组合物和用其治疗或预防病症的方法 | |
CN1229111C (zh) | 延释制剂 | |
CN1183901C (zh) | 胶凝药物组合物 | |
CN1149979C (zh) | 药物组合物 | |
CN1255852A (zh) | 用于紫杉烷类化合物给药的新方法和组合物 | |
CN1061039C (zh) | 环状缩酚酸肽化合物或其盐及其制备方法和用途 | |
CN1076124A (zh) | 一种用于制备含有酸不稳定化合物的肠溶衣口服药的方法 | |
CN1627959A (zh) | 用作丙型肝炎病毒蛋白酶抑制剂的药物组合物 | |
CN1496256A (zh) | 用于治疗增生性疾病的埃博霉素(epo thilone)类似物和化疗剂的组合 | |
CN1108931A (zh) | 口服雷怕霉素配方 | |
CN1738816A (zh) | 作为抗感染化合物的取代的吲哚吡啶鎓 | |
CN1176826A (zh) | 含有环孢菌素的局部用药物组合物 | |
CN1993118A (zh) | 促进眼内渗透性的水性滴眼剂 | |
CN1205929C (zh) | 一种局部给药制剂 | |
CN1076972C (zh) | 经皮肤给药的基剂组合物及其药剂组合物 | |
CN1210463A (zh) | 透明双氯芬酸钠的水溶液以及它的药物组合物 | |
CN1894251A (zh) | (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型 | |
CN101058568A (zh) | 桂哌齐特的新的药用盐及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: BIOLOGY MEDICINE CO., LTD. Free format text: FORMER OWNER: MATRIX PHARMACEUTICAL, INC. Effective date: 20040521 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20040521 Address after: American California Applicant after: Matrix Pharmaceutical, Inc. Address before: American California Applicant before: Matrix Pharmaceutical, Inc. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TACITUS TREATMENT CO., LTD. Free format text: FORMER NAME OR ADDRESS: BIOLOGY MEDICINE CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: American California Patentee after: Yingtaxi for Limited by Share Ltd Address before: American California Patentee before: Matrix Pharmaceutical, Inc. |
|
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |